Provectus’s Substack

Provectus’s Substack

Home
Archive
About
Understanding Rose Bengal Sodium: Biotech Blind Spots and Systems Thinking
For nearly 150 years, rose bengal was seen as a dye. That’s all it’s been allowed to be in the modern pharmaceutical world, until a small biotech began…
 • 
Provectus Biopharmaceuticals
Reprogramming the Code of Disease: Why Provectus’s Small Molecule Rose Bengal Sodium May Act Like a Biological Operating System
For decades, pharmaceutical companies have trained us to think in indications.
 • 
Provectus Biopharmaceuticals
Do Immune Checkpoint Inhibitors Truly Deserve the Label “Immunotherapy?”
And…is it time we rethink what that label even means?
 • 
Provectus Biopharmaceuticals
Most Popular
View all
From Survive to Strategize: The Two Eras of Capital Raising at Provectus Biopharmaceuticals (PVCT)
 • Provectus Biopharmaceuticals
From Snake Oil to Systems Reprogrammer: What Tennessee Taught Rose Bengal
 • Provectus Biopharmaceuticals
All Eyes on Bascom Palmer
 • Provectus Biopharmaceuticals
Provectus Info
 • Provectus Biopharmaceuticals
VisiRose: Provectus’s Founded Entity in Ophthalmology
 • Provectus Biopharmaceuticals
Timing vs. Biology: The Era of Rose Bengal Sodium-based Medicines Will Be System-Aware, Not Schedule-Bound
 • Provectus Biopharmaceuticals
“What the Market Can Bear:” Drug Pricing, Capital Discipline, and the Case for a Smarter Biotech Model
The future doesn’t have to be priced like the past
 • 
Provectus Biopharmaceuticals
From Snake Oil to Systems Reprogrammer: What Tennessee Taught Rose Bengal
When new leadership stepped in at Provectus in 2017—armed with strategy, spreadsheets, stubbornness, and Southern grit—there were two phrases hanging…
 • 
Provectus Biopharmaceuticals
Health Tech: Edward Pershing Of VisiRose On How Their Technology Can Make An Important Impact On Our Overall Wellness
Published in Authority Magazine: An Interview With David Leichner
 • 
Provectus Biopharmaceuticals
Timing vs. Biology: The Era of Rose Bengal Sodium-based Medicines Will Be System-Aware, Not Schedule-Bound
For decades, much of the healthcare industry has treated time as a stand-in for the real understanding of biology when treating disease.
 • 
Provectus Biopharmaceuticals
From Survive to Strategize: The Two Eras of Capital Raising at Provectus Biopharmaceuticals (PVCT)
There are two very different chapters in the capital markets and market capitalization history of Provectus Biopharmaceuticals:
 • 
Provectus Biopharmaceuticals
Provectus Info
VisiRose & Topical PV-305 • Published mNET paper & Intralesional PV-10 • Published RB-PDAT paper & Topical PV-305 • 2024 Form 10-K & Intellectual…
 • 
Provectus Biopharmaceuticals
Provectus Info
VisiRose & Topical PV-305 • Tex’s Journey & Intralesional PV-10 • Veripure Trademark Updatem • PDAC and Intralesional PV-10 • VisiRose: Bascom Palmer…
 • 
Provectus Biopharmaceuticals
Provectus’s Substack
Provectus’s Substack
A clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of synthetic small molecule halogenated xanthenes, with lead molecule rose bengal sodium.

Provectus’s Substack

AboutArchiveSitemap
© 2025 Provectus Biopharmaceuticals, Inc.
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture